image

About Us

A Laser Focus on Developing Curative Cancer Immunotherapies

TargaZyme is poised to revolutionize patient outcomes through our proprietary novel cancer immunotherapies. Our groundbreaking therapeutic solution addresses critical unmet medical challenges in cancer medicine, especially, with regard to enabling curative hematopoietic stem-cell transportation to become safer and more efficacious with TZ 101 and developing our next-generation Tumor Infiltrating Lympocyte (TIL) therapies i.e FucoTILs with the goal to transform survival for late-stage cancer patients with solid cancer tumors.

We are laser-focused on the development of our breakthrough proprietary cell therapies that use specialized immune cells from the patient or the donor to target/eliminate cancer cells regulate and treat inflammation and life-threatening side effects from standard-of-care cancer therapies. Powered by our innovative proprietary cell efficacy multiplier technology, our cancer immunotherapy drugs aim to simultaneously enable precise immune cell delivery to the disease sites as well as amplification of the innate power of the patient’s immune cells to effectively eradicate, cure and even prevent cancer. This approach has shown great promise in preclinical and clinical trials with successfully treating blood cancers, solid cancer tumors, autoimmune diseases, and regenerative medicine.

TargaZyme is an early pioneer of cellular therapy and has accumulated the experience of advancing a portfolio of innovative products, achieving regulatory milestones including a Phase 3 Special Protocol Assessment (SPA) award from the FDA, and obtaining multiple FDA orphan-drug designations and a BLA pathway that enables 12 years of protection from generic drugs. Targazyme has been awarded 27 worldwide patents with more than 10 patent applications pending. The technology has been validated through multiple independent peer-reviewed prestigious medical and scientific publications and receipt of $50M+ of notable medical and scientific awards for the advancement of the fucosylation platform technology. Furthermore, we have built strategic partnerships with leading cancer centers such as MD Anderson Cancer Center, Harvard, University of Pennsylvania Medical Center, Yale Medical Center, corporate partners such as Kyowa Hakko Kirin, VidaCord of Spain, ThermoFisher, AVID Bioscience, Aragen, George Clinical, and NIH/NCI.

As we continue to advance medical innovation, we remain committed to pushing the boundaries of what is possible to accomplish our mission. Our cutting-edge products represent a transformative approach that promises to deliver curative cell-based therapies ultimately to successfully treat, cure and even prevent cancer.

  • boardofdirector4
    Lynnet Koh, MS, MBA
    Chairman / CEO About Me
  • boardofdirector1
    Paul Grint, MD
    Acting CMO & Medical Board Chair About Me
  • management9
    Chuck Olson, PhD
    Chief Technology Officer About Me
  • management7
    Reid Bissonnette PhD
    Senior Director, Immuno-Oncology About Me
  • management6
    Sin-Ho Jung, PhD
    Lead Bio-Statistician About Me
  • management4
    Andrew Zloza, MD, PhD
    VP, Translational Research About Me
  • management3
    Philip Ma, MBA
    Director of Business Development About Me
  • management2
    Ashok Srivastava, MD, PhD, MBA
    Medical Officer, Safety About Me
  • management1
    Audrey Jakuwboski, PhD
    Sr. VP of Regulatory Affairs & Quality About Me
  • Gopal
    Gopal Ramakrishnan Ph.D.
    Project Manager,Administrator About Me
  • cha
    Chaozhong Zou Ph.D.
    Scientific Advisor About Me
  • Bret
    Bret McMillan
    Accounting and Finance About Me
  • boardofdirector4
    Lynnet Koh, MS, MBA
    Chairman / CEO About Me
  • boardofdirector1
    Paul Grint, MD
    Acting CMO & Medical Board Chair About Me
  • ourteam3
    Alan J. Lewis, PhD
    Founding Director Emeritus About Me
  • boardofdirector2
    James S. Manuso, PhD, MBA
    Chief Transaction Advisor About Me
  • Gopal
    Gopal Ramakrishnan Ph.D.
    Project Manager,Administrator About Me
  • boardofdirector3
    Donggou (David) He, MD, PhD
    CMC Advisory Board Director About Me
  • ourteam1
    Lijun Xia, MD, PhD
    Technical Founder & Inventor About Me
  • ourteam2
    Rodger McEver, MD
    Technical Founder & Inventor About Me
  • ourteam4
    Gheath Al-Atrash MD, PhD
    Leading Physician Scientist at MD Anderson Cancer Center About Me
  • ourteam3
    Alan J. Lewis, PhD
    Founding Director Emeritus About Me
  • ourteam1
    Lijun Xia, MD, PhD
    Technical Founder & Inventor About Me
  • ourteam2
    Rodger McEver, MD
    Technical Founder & Inventor About Me
  • ourteam4
    Gheath Al-Atrash MD, PhD
    Leading Physician Scientist at MD Anderson Cancer Center About Me